Synergistic anti-tumor effects of zoledronic acid and radiotherapy against metastatic hepatocellular carcinoma

Kazuhiko Morii, Yuhki Aoyama, Shinichiro Nakamura, Hiroaki Okushin

Research output: Contribution to journalArticle

Abstract

A 72-year-old man with advanced hepatocellular carcinoma and decompensated hepatitis C virus-related cirrhosis suffered from a metastatic femoral fracture. After undergoing radiotherapy, he was only treated with supportive care, except for the administration of zoledronic acid (ZA). Thereafter, the initially elevated serum a-fetoprotein and des-gamma carboxyprothrombin levels declined to within the normal ranges. Hepatic and metastatic adrenal tumors, distant from the radiation field, exhibited a surprising regression. ZA is known to inhibit the activity of osteoclasts, bone-residential macrophages, and has been reported to have a direct antitumor effect. ZA may adjust the immunological milieu in tumor microenvironments by inhibiting the tumorassociated macrophages. Because radiotherapy can enhance the presentation of tumor-associated antigens, ZA and radiotherapy may exert synergistic anti-tumor effects.

Original languageEnglish
Pages (from-to)2609-2613
Number of pages5
JournalInternal Medicine
Volume54
Issue number20
DOIs
Publication statusPublished - Oct 15 2015

Fingerprint

zoledronic acid
Hepatocellular Carcinoma
Radiotherapy
Neoplasms
Macrophages
Fetal Proteins
Femoral Fractures
Tumor Microenvironment
Glandular and Epithelial Neoplasms
Neoplasm Antigens
Osteoclasts
Hepacivirus
Reference Values
Fibrosis
Radiation
Bone and Bones
Liver
Serum

Keywords

  • Hepatocellular carcinoma
  • Radiotherapy
  • Tumor microenvironment
  • Tumor-associated macrophage
  • Zoledronic acid

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Synergistic anti-tumor effects of zoledronic acid and radiotherapy against metastatic hepatocellular carcinoma. / Morii, Kazuhiko; Aoyama, Yuhki; Nakamura, Shinichiro; Okushin, Hiroaki.

In: Internal Medicine, Vol. 54, No. 20, 15.10.2015, p. 2609-2613.

Research output: Contribution to journalArticle

Morii, Kazuhiko ; Aoyama, Yuhki ; Nakamura, Shinichiro ; Okushin, Hiroaki. / Synergistic anti-tumor effects of zoledronic acid and radiotherapy against metastatic hepatocellular carcinoma. In: Internal Medicine. 2015 ; Vol. 54, No. 20. pp. 2609-2613.
@article{aef7ecca750342ea9ad598fd7071c3e8,
title = "Synergistic anti-tumor effects of zoledronic acid and radiotherapy against metastatic hepatocellular carcinoma",
abstract = "A 72-year-old man with advanced hepatocellular carcinoma and decompensated hepatitis C virus-related cirrhosis suffered from a metastatic femoral fracture. After undergoing radiotherapy, he was only treated with supportive care, except for the administration of zoledronic acid (ZA). Thereafter, the initially elevated serum a-fetoprotein and des-gamma carboxyprothrombin levels declined to within the normal ranges. Hepatic and metastatic adrenal tumors, distant from the radiation field, exhibited a surprising regression. ZA is known to inhibit the activity of osteoclasts, bone-residential macrophages, and has been reported to have a direct antitumor effect. ZA may adjust the immunological milieu in tumor microenvironments by inhibiting the tumorassociated macrophages. Because radiotherapy can enhance the presentation of tumor-associated antigens, ZA and radiotherapy may exert synergistic anti-tumor effects.",
keywords = "Hepatocellular carcinoma, Radiotherapy, Tumor microenvironment, Tumor-associated macrophage, Zoledronic acid",
author = "Kazuhiko Morii and Yuhki Aoyama and Shinichiro Nakamura and Hiroaki Okushin",
year = "2015",
month = "10",
day = "15",
doi = "10.2169/internalmedicine.54.4430",
language = "English",
volume = "54",
pages = "2609--2613",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "20",

}

TY - JOUR

T1 - Synergistic anti-tumor effects of zoledronic acid and radiotherapy against metastatic hepatocellular carcinoma

AU - Morii, Kazuhiko

AU - Aoyama, Yuhki

AU - Nakamura, Shinichiro

AU - Okushin, Hiroaki

PY - 2015/10/15

Y1 - 2015/10/15

N2 - A 72-year-old man with advanced hepatocellular carcinoma and decompensated hepatitis C virus-related cirrhosis suffered from a metastatic femoral fracture. After undergoing radiotherapy, he was only treated with supportive care, except for the administration of zoledronic acid (ZA). Thereafter, the initially elevated serum a-fetoprotein and des-gamma carboxyprothrombin levels declined to within the normal ranges. Hepatic and metastatic adrenal tumors, distant from the radiation field, exhibited a surprising regression. ZA is known to inhibit the activity of osteoclasts, bone-residential macrophages, and has been reported to have a direct antitumor effect. ZA may adjust the immunological milieu in tumor microenvironments by inhibiting the tumorassociated macrophages. Because radiotherapy can enhance the presentation of tumor-associated antigens, ZA and radiotherapy may exert synergistic anti-tumor effects.

AB - A 72-year-old man with advanced hepatocellular carcinoma and decompensated hepatitis C virus-related cirrhosis suffered from a metastatic femoral fracture. After undergoing radiotherapy, he was only treated with supportive care, except for the administration of zoledronic acid (ZA). Thereafter, the initially elevated serum a-fetoprotein and des-gamma carboxyprothrombin levels declined to within the normal ranges. Hepatic and metastatic adrenal tumors, distant from the radiation field, exhibited a surprising regression. ZA is known to inhibit the activity of osteoclasts, bone-residential macrophages, and has been reported to have a direct antitumor effect. ZA may adjust the immunological milieu in tumor microenvironments by inhibiting the tumorassociated macrophages. Because radiotherapy can enhance the presentation of tumor-associated antigens, ZA and radiotherapy may exert synergistic anti-tumor effects.

KW - Hepatocellular carcinoma

KW - Radiotherapy

KW - Tumor microenvironment

KW - Tumor-associated macrophage

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84944472796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944472796&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.54.4430

DO - 10.2169/internalmedicine.54.4430

M3 - Article

C2 - 26466697

AN - SCOPUS:84944472796

VL - 54

SP - 2609

EP - 2613

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 20

ER -